Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548594 · ClinicalTrials.gov registry record · NA
Out of State - tAN hEDS
A NA study of Hypermobile EDS (hEDS), sponsored by Medical University of South Carolina.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06548594: Active NA study of Hypermobile EDS (hEDS), sponsored by Medical University of South Carolina.
NCT06548594 is a NA study of Hypermobile EDS (hEDS) that is active but no longer recruiting, run by Medical University of South Carolina. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06548594, a NA study of Hypermobile EDS (hEDS), is active but no longer recruiting, sponsored by Medical University of South Carolina.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypermobile EDS and hypermobile spectrum disorder (collectively referred to as hEDS) are estimated to affect 1 in 500 individuals worldwide. hEDS patients have limited treatment options for their numerous symptoms that impact the quality of life. This clinical trial tests a new ear stimulation method in hEDS patients to determine if it may improve quality of life.
Primary Outcome
The investigators have created an Ehlers-Danlos Syndrome Symptom Battery that measures a variety of different primary and secondary symptoms associated with Ehlers-Danlos Syndrome, including: Pain, Fatigue, Sleep, Anxiety, Depression, Quality of Life, and Gastrointestinal issues.
Conditions Studied
Interventions
- DEVICE Transcutaneous Auricular Neurostimulation
Study Locations (1)
South Carolina
- Medical University of South Carolina Institute of Psychiatry - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2026-04-01 |
| Phase | NA |
What the registry record for NCT06548594 still lists
NCT06548594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hypermobile EDS (hEDS) appearing as the primary indexed condition, and to 1 intervention - of which Transcutaneous Auricular Neurostimulation is the first listed.
NCT06548594 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06548594 about?
NCT06548594 is a clinical study titled "Out of State - tAN hEDS". Hypermobile EDS and hypermobile spectrum disorder (collectively referred to as hEDS) are estimated to affect 1 in 500 individuals worldwide. hEDS patients have limited treatment options for their numerous symptoms that impact the quality of life. This clinical trial tests a new ear stimulation metho...
What is the current status of trial NCT06548594?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-11-27. Estimated completion is 2026-04-01.
What conditions does trial NCT06548594 study?
This clinical trial studies the following conditions: Hypermobile EDS (hEDS).
What interventions are being tested in trial NCT06548594?
The interventions under investigation include: Transcutaneous Auricular Neurostimulation (DEVICE).
Who is sponsoring clinical trial NCT06548594?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548594 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06548594's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI